<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270333</url>
  </required_header>
  <id_info>
    <org_study_id>GaziU</org_study_id>
    <nct_id>NCT02270333</nct_id>
  </id_info>
  <brief_title>Inspiratory Muscle Training in Sarcoidosis</brief_title>
  <official_title>Effects of Inspiratory Muscle Training in Patients With Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gazi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gazi University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory muscle weakness results with decreased exercise capacity, worse fatigue, dyspnea
      and quality of life in patients with sarcoidosis. However, no study investigated the effects
      of inspiratory muscle training (IMT), therefore effects of IMT on outcomes in patients with
      sarcoidosis were investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were diagnosed with sarcoidosis according to the criteria of the latest American
      Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis
      and Other Granulomatous (WASOG) Disorders statement on sarcoidosis. Primary outcome
      measurement was respiratory muscle strength, secondary outcomes were, exercise capacity
      quality of life, fatigue and depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum inspiratory and expiratory muscle strength (MIP, MEP)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mouth pressure device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>6 weeks</time_frame>
    <description>Six-minute walk test (6MWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Exercise Capacity</measure>
    <time_frame>6 weeks</time_frame>
    <description>Modified incremental shuttle walk test (ISWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 weeks</time_frame>
    <description>Fatigue Severity Scale (FSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function and diffusing capacity</measure>
    <time_frame>6 weeks</time_frame>
    <description>Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral muscle strength</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hand-held dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>6 weeks</time_frame>
    <description>Modified Borg and Modified Medical Research Council (MMRC) dyspnea scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>6 weeks</time_frame>
    <description>Montgomery Asberg Depression Rating Scale (MADRS))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 weeks</time_frame>
    <description>Saint George's Respiratory Questionnaire (SGRQ) (Turkish versions of all scales)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inspiratory muscle training</intervention_name>
    <description>Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).
The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.
The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham inspiratory muscle training</intervention_name>
    <description>Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).
The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically stable

          -  Under standard medication

          -  Stage I and IV

          -  No change in medications over three months

        Exclusion Criteria:

          -  Cognitive disorders

          -  Current corticosteroid use

          -  Having co-morbidity to prevent performing IMT

          -  Acute infection

          -  Orthopedic and neurological problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Müşerrefe Nur Karadallı, MSc.</last_name>
    <role>Study Chair</role>
    <affiliation>Gazi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Burcu Camcıoğlu, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gazi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meral Boşnak Güçlü, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gazi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nurdan Köktürk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gazi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haluk Türktaş, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gazi University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, Demedts MG, Decramer M. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005 Jan;60(1):32-8.</citation>
    <PMID>15618580</PMID>
  </results_reference>
  <results_reference>
    <citation>Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Müller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006 Nov;130(5):1496-502.</citation>
    <PMID>17099029</PMID>
  </results_reference>
  <results_reference>
    <citation>Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001 Jul;120(1):102-8.</citation>
    <PMID>11451823</PMID>
  </results_reference>
  <results_reference>
    <citation>Wirnsberger RM, Drent M, Hekelaar N, Breteler MH, Drent S, Wouters EF, Dekhuijzen PN. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J. 1997 Jul;10(7):1450-5.</citation>
    <PMID>9230229</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>October 18, 2014</last_update_submitted>
  <last_update_submitted_qc>October 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gazi University</investigator_affiliation>
    <investigator_full_name>Meral Boşnak Güçlü</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>inspiratory muscle strength</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

